Human Vaccines & Immunotherapeutics (Nov 2017)

Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants

  • James A. Church,
  • Sandra Rukobo,
  • Margaret Govha,
  • Marya P. Carmolli,
  • Sean A. Diehl,
  • Bernard Chasekwa,
  • Robert Ntozini,
  • Kuda Mutasa,
  • Jean H. Humphrey,
  • Beth D. Kirkpatrick,
  • Andrew J. Prendergast

DOI
https://doi.org/10.1080/21645515.2017.1359454
Journal volume & issue
Vol. 13, no. 11
pp. 2543 – 2547

Abstract

Read online

It remains uncertain whether HIV-exposed uninfected (HEU) infants have impaired responses to oral vaccines. We performed a cross-sectional study of 6-month-old infants recruited at birth to the ZVITAMBO trial in Zimbabwe between 1997–2001, before introduction of prevention of mother-to-child transmission interventions. We measured poliovirus-specific IgA to type 1–3 polio strains by semi-quantitative capture ELISA in cryopreserved serum samples collected from 85 HEU and 101 HIV-unexposed infants at 6 months of age, one month after their last immunisation with trivalent OPV. Almost all infants were breastfed, with the majority in both groups mixed breastfed (70.6% HEU versus 71.3% HIV-unexposed). Median (IQR) vaccine titers for HEU and HIV-unexposed infants were 1592 (618–4896) vs. 1774 (711–5431) for Sabin 1 (P = 0.46); 1895 (810–4398) vs. 2308 (1081–4283) for Sabin 2 (P = 0.52); and 1798 (774–4192) vs. 2260 (996–5723) for Sabin 3 (P = 0.18). There were no significant differences in vaccine titers between HEU and HIV-unexposed infants, suggesting that vertical HIV exposure does not impact oral poliovirus vaccine immunogenicity.

Keywords